Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and TACE in Resectable Hepatocellular Carcinoma
NCT05578430Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Major Pathological Response Rate at 2 years. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05578430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578430.